JP5039027B2 - 結腸癌および膵臓癌のための、組換え型モノクローナル抗体および対応する抗原 - Google Patents

結腸癌および膵臓癌のための、組換え型モノクローナル抗体および対応する抗原 Download PDF

Info

Publication number
JP5039027B2
JP5039027B2 JP2008506789A JP2008506789A JP5039027B2 JP 5039027 B2 JP5039027 B2 JP 5039027B2 JP 2008506789 A JP2008506789 A JP 2008506789A JP 2008506789 A JP2008506789 A JP 2008506789A JP 5039027 B2 JP5039027 B2 JP 5039027B2
Authority
JP
Japan
Prior art keywords
antibody
seq
antibodies
acid sequence
cpaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008506789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008538289A (ja
JP2008538289A5 (enExample
Inventor
マイレン アーレン，
ジェイ． アンドリュー ブリストル，
アリエル シー． ホリンシェッド，
クォン ワイ． ツァン，
Original Assignee
ネオジェニックス オンコロジー， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネオジェニックス オンコロジー， インコーポレイテッド filed Critical ネオジェニックス オンコロジー， インコーポレイテッド
Publication of JP2008538289A publication Critical patent/JP2008538289A/ja
Publication of JP2008538289A5 publication Critical patent/JP2008538289A5/ja
Application granted granted Critical
Publication of JP5039027B2 publication Critical patent/JP5039027B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2008506789A 2005-04-15 2006-04-14 結腸癌および膵臓癌のための、組換え型モノクローナル抗体および対応する抗原 Active JP5039027B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67148105P 2005-04-15 2005-04-15
US60/671,481 2005-04-15
PCT/US2006/014270 WO2006113546A2 (en) 2005-04-15 2006-04-14 Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

Publications (3)

Publication Number Publication Date
JP2008538289A JP2008538289A (ja) 2008-10-23
JP2008538289A5 JP2008538289A5 (enExample) 2011-04-14
JP5039027B2 true JP5039027B2 (ja) 2012-10-03

Family

ID=37115788

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008506789A Active JP5039027B2 (ja) 2005-04-15 2006-04-14 結腸癌および膵臓癌のための、組換え型モノクローナル抗体および対応する抗原

Country Status (6)

Country Link
US (8) US7314622B2 (enExample)
EP (1) EP1871417B1 (enExample)
JP (1) JP5039027B2 (enExample)
AU (1) AU2006236508B2 (enExample)
CA (1) CA2604238C (enExample)
WO (1) WO2006113546A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8535667B2 (en) 2005-04-15 2013-09-17 Precision Biologics, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US11345733B2 (en) 2010-06-22 2022-05-31 Precision Biologics, Inc. Colon and pancreas cancer specific antigens and antibodies

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008284015B2 (en) * 2007-08-03 2014-05-15 Musc Foundation For Research Development Human monoclonal antibodies and methods for producing the same
CN101854946B (zh) 2007-11-08 2013-07-03 尼尔詹尼克斯肿瘤研究公司 结肠癌和胰腺癌的重组单克隆抗体和相应抗原
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
US9050317B2 (en) * 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100111835A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US20100111857A1 (en) 2008-10-31 2010-05-06 Boyden Edward S Compositions and methods for surface abrasion with frozen particles
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US8858912B2 (en) * 2008-10-31 2014-10-14 The Invention Science Fund I, Llc Frozen compositions and methods for piercing a substrate
US8409376B2 (en) 2008-10-31 2013-04-02 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8563012B2 (en) * 2008-10-31 2013-10-22 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8793075B2 (en) * 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8721583B2 (en) * 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8414356B2 (en) * 2008-10-31 2013-04-09 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US9050070B2 (en) * 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9060931B2 (en) * 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US20100111834A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US20100111836A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US9060934B2 (en) * 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8725420B2 (en) * 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8731840B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100111831A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for surface abrasion with frozen particles
US8551505B2 (en) * 2008-10-31 2013-10-08 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100111841A1 (en) * 2008-10-31 2010-05-06 Searete Llc Compositions and methods for surface abrasion with frozen particles
US9060926B2 (en) * 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9056047B2 (en) 2008-10-31 2015-06-16 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8603495B2 (en) * 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8603494B2 (en) * 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8788211B2 (en) * 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8545855B2 (en) * 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8545806B2 (en) * 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
TWI552760B (zh) 2010-02-24 2016-10-11 雷那特神經科學股份有限公司 拮抗劑抗－ｉｌ－７受體抗體及方法
BR112012022917A2 (pt) 2010-03-11 2017-01-10 Pfizer anticorpos com ligação a antígeno dependente de ph
US9068014B2 (en) 2010-09-23 2015-06-30 Precision Biologics, Inc. Colon and pancreas cancer peptidomimetics
US8871908B2 (en) 2011-11-11 2014-10-28 Rinat Neuroscience Corp. Antibodies specific for Trop-2 and their uses
CN104169301A (zh) 2011-12-22 2014-11-26 瑞纳神经科学公司 人生长激素受体拮抗剂抗体及其使用方法
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
BR112015010722A2 (pt) 2012-11-09 2017-08-22 Pfizer Anticorpos específicos de fator de crescimento derivado de plaquetas de isoforma b e composições e usos dos mesmos
US9938344B2 (en) * 2012-12-28 2018-04-10 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
RU2015147721A (ru) 2013-05-07 2017-06-15 Ринат Нейросаенз Корпорэйшн Антитела против рецептора глюкагона и способы их использования
EP3027653A2 (en) 2013-08-02 2016-06-08 Pfizer Inc Anti-cxcr4 antibodies and antibody-drug conjugates
CA2929784C (en) 2013-11-13 2019-11-26 Pfizer Inc. Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
SG11201608953WA (en) 2014-04-30 2016-11-29 Pfizer Anti-ptk7 antibody-drug conjugates
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
MX2017013297A (es) 2015-04-13 2018-06-19 Pfizer Anticuerpos terapeuticos y sus usos.
WO2017015619A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
CN115636880A (zh) 2015-10-23 2023-01-24 辉瑞有限公司 抗il-2抗体及其组合物和用途
US10221242B2 (en) 2016-01-21 2019-03-05 Pfizer Inc. Antibodies specific for epidermal growth factor receptor variant III and their uses
RU2758632C2 (ru) 2016-10-17 2021-11-01 Пфайзер Инк. Антитела против edb и конъюгаты антитело-лекарственное средство
AU2018225153A1 (en) * 2017-02-22 2019-09-19 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
MX2019010458A (es) 2017-03-03 2020-01-20 Rinat Neuroscience Corp Anticuerpos anti-gitr y metodos de uso de los mismos.
TWI757499B (zh) 2017-06-02 2022-03-11 美商輝瑞大藥廠 對flt3具特異性之抗體及其用途
CN117624045A (zh) 2018-01-26 2024-03-01 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
WO2019148043A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
CR20250117A (es) 2018-01-26 2025-05-09 Exelixis Inc COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-0355)
IL322656A (en) 2018-02-01 2025-10-01 Pfizer Chimeric antigen receptors against CD70
US11377500B2 (en) 2018-02-01 2022-07-05 Pfizer Inc. Antibodies specific for CD70 and their uses
BR112020016374A2 (pt) 2018-02-13 2020-12-15 Precision Biologics, Inc. Métodos e composições para direcionar células treg
MX387358B (es) 2018-02-28 2025-03-18 Pfizer Variantes de il-15 y usos de las mismas
EP3797121B1 (en) 2018-05-23 2024-06-19 Pfizer Inc. Antibodies specific for cd3 and uses thereof
MX2020012607A (es) 2018-05-23 2021-01-29 Pfizer Anticuerpos especificos para gucy2c y sus usos.
RS67216B1 (sr) 2018-12-13 2025-10-31 Exelixis Inc Kristalni oblici i oblici soli inhibitora kinaze
CN113710322A (zh) 2019-01-25 2021-11-26 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
JP2020117502A (ja) 2019-01-28 2020-08-06 ファイザー・インク 変形性関節症の徴候および症状を処置する方法
US20220135663A1 (en) 2019-02-18 2022-05-05 Pfizer Inc. Method of treatment of Chronic Low Back Pain
EP3955923A1 (en) 2019-04-18 2022-02-23 The Regents Of The University Of Michigan Combination with checkpoint inhibitors to treat cancer
AU2019449809A1 (en) 2019-06-03 2021-12-16 Exelixis, Inc. Crystalline salt forms of a kinase inhibitor
AR119069A1 (es) 2019-06-04 2021-11-24 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de quinasas
US20240209061A1 (en) 2020-03-09 2024-06-27 Pfizer Inc. Fusion proteins and uses thereof
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
BR112022025667A2 (pt) 2020-06-26 2023-03-07 Pfizer Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a
BR112023000701A2 (pt) 2020-07-17 2023-02-07 Pfizer Anticorpos terapêuticos e usos dos mesmos
US20230314440A1 (en) 2020-08-21 2023-10-05 Exelixis, Inc. Method of treating cancer
WO2022195504A1 (en) 2021-03-19 2022-09-22 Pfizer Inc. Method of treating osteoarthritis pain with an anti ngf antibody
WO2023007374A1 (en) 2021-07-27 2023-02-02 Pfizer Inc. Method of treatment of cancer pain with tanezumab
EP4452947A1 (en) 2021-12-22 2024-10-30 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
IL315262A (en) 2022-03-03 2024-10-01 Pfizer Multiple specific antibodies related to IL-4, IL-13 and/or TSLP and their uses
US20240059799A1 (en) 2022-05-11 2024-02-22 Pfizer Inc. Anti-tl1a antibodies and methods of use thereof
WO2023218320A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
WO2023228082A1 (en) 2022-05-26 2023-11-30 Pfizer Inc. Anti-tnfr2 antibodies and methods of use thereof
CN119278212A (zh) 2022-05-31 2025-01-07 辉瑞大药厂 抗bmp9抗体及其使用方法
PE20250875A1 (es) 2022-06-17 2025-03-28 Pfizer Variantes il-12, anticuerpos anti-pd1, proteinas de fusion y usos de estos
EP4565611A1 (en) 2022-08-03 2025-06-11 Pfizer Inc. Anti- il27r antibodies and methods of use thereof
EP4590699A1 (en) 2022-09-22 2025-07-30 Pfizer Inc. Methods of treatment with ifn-beta antibodies
US20240252614A1 (en) 2023-01-18 2024-08-01 Pfizer Inc. Vaccines against respiratory diseases
WO2024218650A1 (en) 2023-04-19 2024-10-24 Pfizer Inc. Lilrb1 and lilrb2 antibodies and methods of use thereof
WO2024239006A1 (en) 2023-05-17 2024-11-21 Genentech, Inc. Anti-tl1a antibody therapeutic methods
US20250154287A1 (en) 2023-11-10 2025-05-15 Pfizer Inc. ANTI-MIGIS-alpha ANTIBODIES AND METHODS OF USE THEREOF
US20250163168A1 (en) 2023-11-17 2025-05-22 Pfizer Inc. Novel antibodies and antibody conjugates for the treatment of metabolic disorders
WO2025257715A1 (en) 2024-06-12 2025-12-18 Seagen Inc. Anti-ceacam5 antibodies, antibody-drug conjugates and methods of uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1413765A (en) 1973-05-02 1975-11-12 Diamond Int Corp Anti-blister cage mat for raising broilers
GB1438507A (en) 1973-06-27 1976-06-09 Mullard Ltd Magnetic matrix memories
US6190640B1 (en) 1985-04-19 2001-02-20 Ludwig Institute For Cancer Research Method for treating neoplasia using humanized antibodies which bind to antigen A33
US5431897A (en) 1985-04-19 1995-07-11 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
US5851526A (en) 1985-04-19 1998-12-22 Ludwig Institute For Cancer Research Methods of treating colon cancer utilizing tumor-specific antibodies
US4810781A (en) 1987-01-15 1989-03-07 The George Washington University Methods of preparing epitopes of tumor associated antigens
US5688657A (en) * 1988-03-31 1997-11-18 International Bio-Immune Systems, Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2733582B2 (ja) 1991-08-05 1998-03-30 日本ケーブル株式会社 自動循環式索道の搬器荷重検出安全装置
US6307026B1 (en) 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
US5712369A (en) 1995-08-24 1998-01-27 Ludwig Institute For Cancer Research Isolated protein which binds to A33 antibody, and peptides corresponding to portions of the protein
ATE319745T1 (de) 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
US6652853B2 (en) 2001-03-08 2003-11-25 Ludwig Institute For Cancer Research Method for treating cancer using A33 specific antibodies and chemotherapeutic agents
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
WO2003016909A1 (en) 2001-08-16 2003-02-27 Ludwig Institute For Cancer Research Method for determining protein component in a biological sample
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
WO2005041747A2 (en) 2003-06-03 2005-05-12 The Trustees Of The University Of Pennsylvania Stealthy nano agents
AU2006236508B2 (en) * 2005-04-15 2012-02-02 Precision Biologics, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US20130189268A1 (en) * 2010-06-22 2013-07-25 Precision Biologics, Inc. Colon and pancreas cancer specific antigens and antibodies
US9068014B2 (en) * 2010-09-23 2015-06-30 Precision Biologics, Inc. Colon and pancreas cancer peptidomimetics
US9938344B2 (en) * 2012-12-28 2018-04-10 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
US11279768B1 (en) * 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8535667B2 (en) 2005-04-15 2013-09-17 Precision Biologics, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US9169326B2 (en) 2005-04-15 2015-10-27 Precision Biologics, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US9605077B2 (en) 2005-04-15 2017-03-28 Precision Biologics, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US10364295B2 (en) 2005-04-15 2019-07-30 Precision Biologics, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US11572413B2 (en) 2005-04-15 2023-02-07 Precision Biologics, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US12460013B2 (en) 2005-04-15 2025-11-04 Precision Biologics, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US11345733B2 (en) 2010-06-22 2022-05-31 Precision Biologics, Inc. Colon and pancreas cancer specific antigens and antibodies

Also Published As

Publication number Publication date
WO2006113546A3 (en) 2009-04-30
US9169326B2 (en) 2015-10-27
US20110158902A1 (en) 2011-06-30
US8535667B2 (en) 2013-09-17
CA2604238C (en) 2015-07-07
US7763720B2 (en) 2010-07-27
US20190322759A1 (en) 2019-10-24
US20150353644A1 (en) 2015-12-10
EP1871417A4 (en) 2010-01-06
EP1871417A2 (en) 2008-01-02
US12460013B2 (en) 2025-11-04
JP2008538289A (ja) 2008-10-23
US20080227965A1 (en) 2008-09-18
US11572413B2 (en) 2023-02-07
US9605077B2 (en) 2017-03-28
US20230203190A1 (en) 2023-06-29
AU2006236508A1 (en) 2006-10-26
US7314622B2 (en) 2008-01-01
CA2604238A1 (en) 2006-10-26
US10364295B2 (en) 2019-07-30
AU2006236508B2 (en) 2012-02-02
WO2006113546A2 (en) 2006-10-26
US20100310559A1 (en) 2010-12-09
US20070020273A1 (en) 2007-01-25
US20170218080A1 (en) 2017-08-03
EP1871417B1 (en) 2013-09-11

Similar Documents

Publication Publication Date Title
US12460013B2 (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US11952429B2 (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
HK1149483B (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
BRPI0819262B1 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo, seus usos, e método in vitro de diagnóstico de carcinoma pancreático ou colorretal de um indivíduo

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110222

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20110629

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111102

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120229

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120518

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120607

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120706

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150713

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5039027

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250